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B lymphocytes are among the first cells to be infected by mouse mammary tumor virus (MMTV), and they
play a crucial role in its life cycle. To study transcriptional regulation of MMTV in B cells, we have analyzed
two areas of the long terminal repeat (LTR) next to the glucocorticoid receptor binding site, fp1 (at position
2139 to 2146 from the cap site) and fp2 (at 2157 to 2164). Both showed B-cell-specific protection in DNase
I in vitro footprinting assays and contain binding sites for Ets transcription factors, a large family of proteins
involved in cell proliferation and differentiation and oncogenic transformation. In gel retardation assays, fp1
and fp2 bound the heterodimeric Ets factor GA-binding protein (GABP) present in B-cell nuclear extracts,
which was identified by various criteria: formation of dimers and tetramers, sensitivity to pro-oxidant condi-
tions, inhibition of binding by specific antisera, and comigration of complexes with those formed by recombi-
nant GABP. Mutations which prevented complex formation in vitro abolished glucocorticoid-stimulated tran-
scription from an MMTV LTR linked to a reporter gene in transiently transfected B-cell lines, whereas they
did not affect the basal level. Exogenously expressed GABP resulted in an increased level of hormone response
of the LTR reporter plasmid and produced a synergistic effect with the coexpressed glucocorticoid receptor,
indicating cooperation between the two. This is the first example of GABP cooperation with a steroid receptor,
providing the opportunity for studying the integration of their intracellular signaling pathways.
Mouse mammary tumor virus (MMTV) is a type B retrovi-
rus which causes carcinomas of the mammary gland in females
of susceptible mouse strains (8, 13). The carcinogenic trans-
formation results from transcriptional activation of a particular
class of cellular oncogenes (int genes; reviewed in reference
59). The mammary gland specificity of the oncogenic property
of MMTV depends on the high viral replication rate and con-
sequent high reinfection rate in the mammary epithelial cells,
which are stimulated by pregnancy-related hormones. This
hormonal stimulation has made the MMTV promoter the best-
studied model for investigating the regulation of gene expres-
sion by steroid hormones (for a review, see references 7 and
51). Glucocorticoids, progesterone, and androgens (but not
estrogens) strongly stimulate the rate of MMTV transcription
through the binding of hormone-receptor complexes in the
hormone regulatory element (HRE) (see Fig. 1) region of the
proviral DNA, located upstream of the promoter in the long
terminal repeat (LTR). Binding sites for additional transcrip-
tion factors have been characterized, in particular for CTF
(also called nuclear factor 1 [NF-1]) and Oct-1 in the HRE,
and for mammary gland-specific factors further upstream in
the LTR (reviewed in reference 31).
During primary infection, MMTV is transmitted in the milk
from the mother to the newborn and is taken up in the intes-
tine, where it infects local lymphocytes (reviewed in reference
43). Infected B cells express a 39-LTR-encoded superantigen
(Sag) on their surfaces that interacts with the Vb domain of the
T-cell receptor on specific T-cell subsets (reviewed in reference
1). This immune reaction results in a preferential clonal ex-
pansion of infected B cells, thus facilitating the persistence of
the virus in the organism until the target mammary tissue
develops. The biology of the latency phase of the viral life cycle
is still largely unknown. Lymphocytes are required for virus
transportation to the mammary gland, where the hormonal
stimulation is the most important factor for virus production
and tumorigenicity. However, lower levels of virus expression
are also detected in a specific set of organs, in particular in
lymphoid tissues. Tight control of viral gene expression is sug-
gested by the observations that (i) the pattern of expressing
organs in mice transgenic for a reporter gene linked to the
MMTV LTR is the same as that in an infected mouse and (ii)
the presence of hormone receptors is not sufficient to allow
LTR activation in a nonpermissive organ (reference 52 and
references therein). Since B lymphocytes are essential for virus
propagation in the infected animal (33), we are interested in
the regulation of viral expression in these cells. As this implies
the activation of the standard proviral promoter in the LTR for
the synthesis of genomic and spliced RNAs, we investigated
the sequence requirements and interacting transcription fac-
tors in B-lymphoma cell lines used as a model.
Both B and T cells have been shown to be infected in the
mouse and in cell culture and to be able to transmit virus to
other cells (21). Earlier studies were focused on pathological
situations, in particular on T-cell lymphomas characterized by
an amplification of integrated proviruses carrying large dele-
tions and rearrangements in their LTRs (reference 62 and
references therein). Lymphocytes of the B lineage, B-cell lines,
and B lymphomas express endogenous MMTV sequences at
detectable levels, without amplification or rearrangement of
the proviral DNA (reviewed in reference 16). In this study, we
analyzed the activity of the main LTR promoter in mature
B-cell lines. We uncovered two sequences which are required
for glucocorticoid stimulation in B cells and showed that they
bind proteins of the Ets family of transcription factors, namely,
the heterodimeric GA-binding protein (GABP) (10, 37, 38).
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The DNA-binding component is the a subunit (GABPa) con-
taining the conserved Ets domain, a winged helix-turn-helix
protein motif (6). The b subunit (GABPb) is bound to GABPa
via repeats of the Notch-ankyrin type (19). On two neighboring
sites in the DNA, tetramers are formed by interaction between
the b subunits, and all these protein-protein interactions
greatly stabilize the binding to DNA (reviewed in reference
28). Both DNA binding and heterodimerization are regulated
by the reduction-oxidation state of specific cysteine residues
(15, 45). We also demonstrated, using transient-transfection
assays in B-cell lines with LTR constructs carrying specific
mutations, that both Ets sites are important for glucocorticoid
stimulation, whereas they were not involved in the basal level
of transcription. Exogenously expressed GABP increased the
hormone-induced level of transcription, as did exogenously
expressed glucocorticoid receptor, and both required the in-
tegrity of the Ets sites. Coexpressed receptor and GABP re-
sulted in a synergistic potentiation, suggesting a functional
cooperation between GABP and the glucocorticoid receptor in
MMTV transcription in B cells.
MATERIALS AND METHODS
Cell lines. The M12.4 mouse B-lymphoma cell line (M12) was cultured in
Dulbecco modified eagle’s medium (DMEM) containing 5% heat-inactivated
fetal calf serum (FCS), 50 mM 2-mercaptoethanol, 2 mM L-glutamine, and
antibiotics. The A20 mouse B-lymphoma cell line was grown in RPMI 1640
medium, 10% FCS, antibiotics, and 50 mM 2-mercaptoethanol. Both were from
R. Lees, Ludwig Institute for Cancer Research, Epalinges, Switzerland. Ltk2
aprt2 cells (mouse fibroblasts) were maintained in DMEM, 10% FCS, and
antibiotics. Cultures were kept at 37°C in a humidified 5% CO2 atmosphere.
Reagents and expression plasmids. The expression plasmids sRSV-GABPa
and sRSV-GABPb1, bacterially expressed recombinant GABPa and GABPb1,
and rabbit polyclonal antibodies against these proteins (23) were kind gifts of E.
Flory. Immunoglobulin Gs (IgGs) were purified with HiTrap protein G affinity
columns (Pharmacia). pCMV-thioredoxin was a gift of I. Kerblat, the human
glucocorticoid receptor expression plasmid pRSV-hGRa (26) was a gift of R.
Evans, and the mouse glucocorticoid receptor expression plasmid pSG5mGR
(derived from pSV2GRWrec [18]) was a gift of M. G. Parker.
Plasmid construction. The wild-type MMTV LTR (GR strain; from the PstI
site at position 11 in the LTR to the PvuII site at its 39 end: pLSwt [36]) and the
mutants LS 2175/2166 and D2193/2162 (carrying an octameric HindIII linker
inserted between the indicated positions from the RNA start site [12]) were
subcloned as SalI (filled-in)-BamHI fragments into the firefly luciferase pGL3-
Basic vector (Promega) at the SmaI and BglII sites. The pGL3 constructs with
LTRs truncated at position 2303 were made in the same vector by inserting the
fragment from 2303 (filled-in StyI site) to the artificial BamHI site next to the 39
end of the LTR. The negative-control plasmid DP (lacking the standard basal
promoter) was made from pGL3/LTRwt by isolating the fragment from the SacI
site in the polylinker upstream of the LTR to the internal SacI site at position
2105 and recloning it into a SacI-cut pGL3-Basic vector. Mutagenesis of the fp1
and fp2 sites was performed by the method of splicing by overlap extension (34).
Briefly, two internal primers of 56 nucleotides containing the two mutated areas
(in boldface below) corresponding to the observed footprints fp1 and fp2 and an
internal SpeI restriction site (underlined) created by a single-nucleotide mutation
at position 2151 (boldface and underlined) were synthesized: left (2174 to
2119) 59 TTCTTAAACACCTTCGTGGAGACTAGTGTGGGAAATAGTTGG
TTTGGTATCAAATG 39 and right (2131 to 2186) 59 AACCAACTATTTCC
CACACTAGTCTCCACGAAGGTGTTTAAGAACAGTTTGTAACC 39. We
also used two external primers: left, (2668) 59 GAGAGCAGTACAAGGAC
TAA 39, and right, (1131) 59 CGCAGTCGGCCGACCTGAGGG 39. Two
PCRs were carried out first: one with the internal primer right and the external
left, and the second with the internal primer left and the external right. After gel
purification, the products were combined in a third PCR using only the external
primers. The final product was digested with StuI and BstEII and recloned in
pGL3/LTRwt to replace the corresponding wild-type fragment. A control LTR
construct with only the SpeI site was generated by mutating the A at 2151 to a
T, using the technique described above but with internal oligonucleotides span-
ning positions 2159 to 2140 and containing the mutation. The presence of the
mutations was verified by sequencing. Recombination of LTR (fp1-fp2) with
LTR (wild type-SpeI) to obtain singly mutated LTRs was performed using the
SpeI site and the StuI or BstEII site.
Transfections. Cell cultures were split the day before transfection to obtain
cultures in the late phase of exponential growth. The amount of reporter plasmid
was chosen to be in the linear range of expression, determined in preliminary
titration experiments. M12, A20, and Ltk2 cells were transfected by the DEAE-
dextran method following different protocols. For M12 cells, after being washed
with a buffer containing 20 mM HEPES (pH 7.2), 137 mM NaCl, 0.5 mM KCl,
and 3 mM glucose, 5 3 106 cells were incubated at 37°C for 1 h with 0.5 ml of
DMEM (without serum) containing DEAE-dextran (200 mg/ml; Amersham
Pharmacia), 0.75 pmol (equal to 3 mg for wild-type LTR) of the LTR-pGL3
constructs, and 50 ng of the Renilla luciferase expression vector pRL-SV40 or
pRL-TK (Promega) and were cultured in complete medium thereafter. The cells
were harvested 24 h after transfection. Transfection experiments with A20 cells
were carried out following a different DEAE-dextran protocol (29). Briefly, 107
cells in 1.5 ml of Tris-saline buffer–DEAE-dextran (500 mg/ml), 0.75 pmol of
LTR constructs, and 50 ng of pRL-SV40 were incubated for 20 min at room
temperature followed by the addition of 10 ml of RPMI–0.1 mM chloroquine
and further incubation for 1 h at 37°C. Finally, the cells were cultured in com-
plete medium and harvested 48 h later. Ltk2 cells were transfected by the
protocol described previously (11) with 0.75 pmol of LTR constructs and 50 ng
of pRL-SV40. When required, the synthetic steroid hormone dexamethasone
was added in all three cell lines 3 to 5 h before harvesting. Luciferase assays were
performed with the Dual luciferase assay kit (Promega), and measurements were
done in a Berthold Lumat luminometer. The results were expressed as the ratio
of firefly luciferase activity to Renilla luciferase activity or, in some cases, when
cotransfected transcription factors affected the level of Renilla luciferase, as
firefly luciferase activity per constant amount of protein (determined by the
bicinchoninic acid assay [Pierce]). The reproducibility of the transfection condi-
tions was verified beforehand. In experimental series, the standard deviation
between independently transfected samples was ,5%.
Nuclear extracts. Extracts were made from logarithmically growing A20 or
M12 B cells (20) with modifications (9). The cells were homogenized in hypo-
tonic buffer, and the nuclei were recovered by centrifugation at 30,000 3 g for
30 s. The nuclei were extracted in buffer C (20 mM HEPES [pH 7.9], 0.2 mM
EDTA, 0.2 mM EGTA, 2 mM dithiothreitol [DTT], 20% glycerol, 0.15 mM
spermine, 0.75 mM spermidine, 1 mM phenylmethylsulfonyl fluoride, 0.4 M
NaCl, and a cocktail of protease inhibitors [Complete and Mini; Roche Molec-
ular Biochemicals]). The extracts were recovered by centrifugation at 300,000 3
g for 45 min and precipitated with ammonium sulfate [0.3 g of solid (NH4)2SO4
per ml of supernatant]. Resuspension, dialysis, and determination of protein
concentration by optical density were performed by the method of Gorski et al.
(27). For the preparation of extracts of A20 cells treated with the oxidant diethyl
maleate (DEM [45]), 1 mM DEM (Sigma) was added to the culture medium 2 h
before harvesting. Nuclear extracts of Ltk2 cells were prepared as described
previously (11).
DNase I footprinting. DNase I footprinting assays were performed by the
following modifications (41, 47) of the original method (24). An asymmetrically
radiolabeled DNA probe was prepared from a plasmid with a truncation at
position 2303 of pLSwt (12), obtained by religating an EcoRI-StyI-cut pLSwt
after filling in with Klenow polymerase. The resulting pLSwt (2303) plasmid was
digested at the (reconstituted) EcoRI site, end labeled with [g-32P]ATP and
polynucleotide kinase, and digested with BamHI. The 0.45-kb fragment was
purified from agarose gels, and an aliquot was used for the purine sequencing
reaction (46). The labeled fragment (10 fmol), 1 mg of double-stranded poly[d(I-
C)] competitor, and nuclear extracts in a 20-ml binding reaction were incubated
on ice for 30 min (11) and digested with DNase I (Roche Molecular Biochemi-
cals) for 5 min at 0°C. Samples without nuclear extracts received a 20-fold
dilution of DNase I for 2 or 5 min. After proteinase K digestion, extraction, and
precipitation (11), the DNA was separated by electrophoresis on 6% denaturing
polyacrylamide gels (46), fixed, and dried prior to autoradiography at 280°C with
intensifying screens.
Gel mobility shift assay. Double-stranded probes were made by annealing a
59-end-labeled oligonucleotide with its unlabeled complementary strand. Their
sequences were as follows: for fp1 (2154 to 2133), 59 GACAAGTGGTTTCC
TGAGTTGG 39 and 59 CCAACTCAGGAAACCACTTGTC 39; for fp2 (2175
to 2152), 59 ggaCTTAAAACAAGGATGTGAGAC 39 and 59 GTCTCACATC
CTTGTTTTAAGtcc 39 (the nucleotides in lowercase letters were added to avoid
an overlap with the glucocorticoid response element [GRE]); for fp1m (mutated
nucleotides are in boldface), 59 GACAAGTGGTGGAAATAGTTGG 39 and 59
CCAACTATTTCCACCACTTGTC 39; for fp2m, 59 ggaCTTAAAACACTTCG
TGGAGAC 39 and 59 GTCTCCACGAAGTGTTTTAAGtcc 39; for fp1-fp2
(equivalent to D, a double oligonucleotide containing both binding sites; 2172/
2133), 59 CCAACTCAGGAAACCACTTGTCTCACATCCTTGTTTTAAG 39
and 59 CTTAAAACAAGGATGTGAGACAAGTGGTTTCCTGAGTTGG 39;
and for VW (promoter of adenovirus 2; position 22/241 [54]), 59 GAAGGGG
GGCTATAAAAGGGGGTGGGGGCGCGTTCGTCC 39 and 59 GGACGAA
CGCGCCCCCACCCCCTTTTATAGCCCCCCTTC 39. Mobility shift assays
were carried out as described previously (17). In brief, 20-ml binding reaction
mixtures in 125 mM HEPES (pH 7.5), 50 mM EDTA, 5 mM DTT, 10% glycerol,
0.5% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride and 12.5 mg of bovine
serum albumin/ml were preincubated with 4 mg of nuclear extracts and 1 mg of
double-stranded poly[d(I-C)] for 10 min at 20°C (the same pattern was observed
at 0°C). Labeled probe (10 fmol) was added, and the reaction was continued for
another 20 min. After the addition of Ficoll 400 to a final concentration of 5%,
the reaction mixtures were loaded onto 5% polyacrylamide gels containing 0.53
Tris-borate-EDTA. The gels were electrophoresed in 0.53 Tris-borate-EDTA
buffer at 4°C for 2 h at 200 V. They were transferred to Whatman 3MM paper,
dried, and autoradiographed. In competition experiments, a 300-fold excess of
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unlabeled, double-stranded oligonucleotides was incubated with the nuclear ex-
tracts 5 min before the probe was added. For the experiments with antibodies, 2
mg of purified IgGs was added to the preincubation mixture on ice for 20 min
prior to addition of the probe, and the reaction was prolonged for 30 min at 20°C.
RESULTS
Identification of binding sites for B-cell nuclear proteins in
the HRE of the MMTV LTR. We demonstrated in a previous
study that tissue-specific factors bind to a DNA sequence im-
mediately 59 to the distal glucocorticoid receptor binding site
(14). We also observed a correlation between the pattern of
protection and the permissivity for MMTV expression of the
mouse organ from which the nuclear extracts were made, e.g.,
spleen (permissive) versus liver (nonpermissive). To look for
cell-type-specific factors, we further analyzed the DNA-protein
interactions occurring in the HRE that are able to modify the
promoter activity. We compared DNase I footprinting patterns
of nuclear extracts from the fibroblastic Ltk2 cell line with
those of a mouse B-lymphoma cell line, M12, which could also
be used for functional studies by transient-expression assays.
Ltk2 cells have been utilized for numerous transcription stud-
ies, as they are permissive for MMTV expression and display
high stimulation factors by glucocorticoid hormones (36, 58).
Neither cell type was treated with glucocorticoid hormones
before the preparation of the extracts. However, as observed
previously (47), crude nuclear extracts from cells with a high
receptor level yield a footprint in the distal GRE even in the
absence of treatment with the hormone, due to residual cyto-
plasmic receptor activated by the ammonium sulfate precipi-
tation. Figure 1 (lanes 5 to 7) shows that M12 cells, which
represent a mature B-cell stage, lack a distinct footprint in the
promoter-distal region (2175 to 2200) that is present in Ltk2
cells (lane 4) and includes the GRE and the upstream tissue-
specific binding site DRa, also seen previously with total spleen
nuclear extracts (14). This indicates that M12 cells most likely
contain a relatively low level of glucocorticoid receptor com-
pared to L cells. In the basal promoter region (240 to 280), a
protection is visible with the M12 extract mainly in the CTF/
NF-I binding site (260 to 280) and also, at high concentra-
tions of extract, in the octamer motif region (240 to 260). The
cap site region (11) is protected by L-cell extracts but not by
M12-cell extracts. In contrast, two narrow areas on the 39 side
of the GRE were specifically protected by M12 nuclear ex-
tracts, one around 2140 (2139 to 2146; called fp1) and the
other around 2160 (2157 to 2164; called fp2).
To assess whether the observed footprints were indeed
caused by proteins bound to fp1 and fp2, an electrophoretic
mobility shift assay was carried out with M12 nuclear extracts
and radiolabeled double-stranded oligonucleotides containing
either fp1 or fp2 (Fig. 2B). Complexes with low mobility were
observed with each probe. The specificity of each complex was
verified by competition, which was apparent using the homol-
ogous unlabeled oligonucleotide (Fig. 2A, lanes 4 and 11) but
not using the unrelated oligonucleotide VW from the adeno-
virus promoter (Fig. 2A, lanes 1 and 7). The fp1 and fp2
complexes had similarly low electrophoretic mobilities (com-
plex I). Cross competition between fp1 and fp2 (Fig. 2A, lanes
5 and 10) indicated that similar binding activities interacted
with these probes. Oligonucleotides containing mutations in
the bases involved in the footprints (Fig. 2B) did not form the
specific complexes when used as probes (Fig. 2A, lanes 14 and
16) and did not compete with the wild-type probes (Fig. 2A,
lanes 2 and 3 and lanes 8 and 9), confirming the specificity of
complex I.
Transcriptional activity of LTRs with mutations in the fp1
and fp2 sites. The same mutations of fp1 and fp2 which elim-
inated the formation of complexes in vitro were engineered
into LTRs (either complete or 59 truncated at 2303 to elimi-
nate the effects of upstream sequences) that directed the syn-
thesis of the firefly luciferase reporter gene. The transcrip-
tional activities of the various plasmids were assayed in
transient-transfection experiments with M12 cells and also, to
confirm the results, with a second B-lymphoma cell line, A20.
FIG. 1. B-cell factors binding in vitro to the HRE of MMTV. DNase I
footprinting analysis with nuclear extracts of the M12 B-cell line shows two
protected sites, fp1 and fp2 (arrowheads), not seen with nuclear extracts of the
fibroblastic Ltk2 cell line. A DNA fragment comprising the sequences from the
StyI restriction site at positions 2303 to 1133, where a synthetic BamHI linker
was inserted, was 59 end labeled at the StyI site. The fragment was incubated
without added proteins (lanes 2 and 3), with 60 mg of nuclear proteins from L
cells (lane 4), or with 48 (lane 5), 72 (lane 6), or 104 (lane 7) mg of nuclear
proteins from M12 cells. The complexes were subjected to DNase I digestion and
separated on a sequencing gel. Lane 1 contains a purine sequencing reaction of
the probe, and the numbers on the left indicate the number of nucleotides from
the transcription start site (11). Also represented in the scheme on the right are
known factor-binding sites in the HRE of the MMTV LTR that are protected by
L-cell extracts: RNA initiation site (CAP), TATA box, binding sites for octamer
factors (OCT), for CTF/NF-1, for the glucocorticoid receptor (the distal GRE),
and for a tissue-specific factor (DRa [14, 47]).
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The measured firefly luciferase activity was standardized with
respect to the activity of a cotransfected plasmid carrying the
Renilla luciferase gene driven by either the simian virus 40
(SV40) promoter or the thymidine kinase promoter of herpes
simplex virus. The cells were either left untreated (to deter-
mine the basal level of promoter activity) or stimulated for 3 to
5 h by the addition of the synthetic glucocorticoid hormone
dexamethasone (at a concentration of 50 nM). Luciferase ac-
tivity was measured in cell extracts prepared 24 (M12 cells) or
48 (A20 cells) h after transfection. None of the mutated con-
structs differed significantly from their wild-type counterparts
in basal promoter activity (Fig. 3A and B, 2dex samples). In
contrast, mutation of both fp1 and fp2 abolished the stimula-
tory effect of dexamethasone in both A20 and M12 cell lines
(Fig. 3A and B, 1 dex samples). Plasmids carrying one muta-
tion, either in fp1 or in fp2, had only a partial activity (Fig. 3A
and B), indicating that both sites contributed roughly equally
to the glucocorticoid induction in B cells. The extent of stim-
ulation by the wild-type LTR was about 10-fold in A20 cells
(Fig. 3A) and about 3-fold in M12 cells (Fig. 3B). The tran-
scriptional activity of the LTR carrying the SpeI site (A-to-T
mutation at position 2151) used for recombining the single fp
site mutations was indistinguishable from that of the wild-type
LTR. An LTR lacking the promoter downstream of position
2105 (Fig. 3, bars DP) was used as a negative control. The
double mutation in fp1 and fp2 also abolished dexamethasone
stimulation with an LTR truncated at position 2303, both in
A20 cells (Fig. 3C) and in M12 cells (not shown). Such trun-
cated plasmids had overall higher expression levels (also under
unstimulated conditions [data not shown]), which were prob-
ably due to the removal of negative regulatory elements
present in the LTR upstream of position 2303 (42). The prox-
imity of fp1 and fp2 to the distal GRE, together with the
observed suppression of the glucocorticoid response in fp1 and
fp2 mutants, suggested that the in vitro complex I may interact
with the glucocorticoid receptor bound in the adjacent GRE
(positions 2171 to 2182). While this sequence element is
essential for the glucocorticoid response in L cells (12), its
function had to be tested in B cells. We therefore performed
transient-expression assays in A20 cells with luciferase reporter
plasmids under the control of an LTR with the distal GRE
deleted (with a HindIII linker replacing the sequence between
2193 and 2162) or an LTR carrying an 8-base substitution in
the GRE (mutant LS 2175/2166). Both plasmids show a 10-
to 20-fold reduction in glucocorticoid response in L cells (12).
As shown in Fig. 3D, both mutants were drastically impaired in
FIG. 2. B-cell nuclear extracts form similar complexes on probes with the fp1 or fp2 sequences. Gel retardation assays (A) with M12 nuclear extracts and end-labeled
oligonucleotide probes (B) are shown. Mutated oligonucleotides (1m and 2m) contained transversions at the positions denoted by asterisks in the sequence in panel
B, where the GRE and the B-cell footprints fp1 and fp2 are underlined and in bold. (A) Protein-DNA complexes were resolved on nondenaturing polyacrylamide gels,
followed by autoradiography. Where indicated (1; above the probes), a 300-fold excess of competitor DNA, either homologous, heterologous, mutated (m), or
nonspecific (vw, an oligonucleotide with the sequence of the adenovirus-2 promoter), was included in the preincubation mixture. Specific complexes with similar
mobilities (I) on fp1 (1) or fp2 (2) showed cross competition (lanes 4, 5, 10, and 11). Mutations in the fp1 (1m) or fp2 (2m) sites abolished the formation of complex
I (lanes 14 and 16), which was not affected by adding fp1m (lanes 3 and 9) or fp2m (lanes 2 and 8) in the competition experiment. ns, nonspecific complex.
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their responses to dexamethasone, demonstrating that the dis-
tal GRE is responsible for the glucocorticoid stimulation of the
MMTV LTR in B cells as well (similar results were obtained in
the M12 cell line [data not shown]). From the results shown in
Fig. 3, we concluded that fp1 and fp2 are required, in addition
to the GRE, for glucocorticoid-stimulated MMTV expression
in these B-cell lines. We were therefore interested in identify-
ing the factors which bind to these glucocorticoid coregulatory
sites in the HRE.
Identification of fp1 and fp2 binding factors from B-lym-
phoma cell lines. The DNA sequence of the HRE was submit-
ted to the World Wide Web Signal Scan Information Matrix
Database Search Service (http://bimas.dcrt.nih.gov/molbio/ma-
trixs/) for analysis of homologies to published recognition se-
quences. The result indicated that fp1 and fp2 could interact
with proteins of the Ets family of transcription factors, which
comprises approximately 30 known members to date. These
are characterized by a common DNA-binding Ets domain of
approximately 85 amino acids, and they are involved in cell
proliferation and differentiation and embryonic development
(reviewed in reference 60). The most likely candidates were
GABP, at both fp1 and fp2, and PEA3, for which a consensus
binding sequence is present in fp2. PEA3 is a single-polypep-
tide Ets factor first described as a regulator of the polyomavi-
rus enhancer (61), while GABP is a heterodimeric DNA-bind-
ing complex originally isolated as a factor involved in
immediate-early gene activation of herpes simplex virus type 1
(37, 38). A human homolog is nuclear respiratory factor 2
(NRF-2, or E4TF-1 [30, 53]). GABP is composed of two dis-
tinct subunits, GABPa, which binds DNA via an Ets domain,
and GABPb, which interacts in a highly specific manner with
GABPa (10) through Notch-ankyrin repeats, thereby greatly
stabilizing GABPa binding to DNA. To test whether GABP
from B cells binds to fp1 and fp2, we carried out gel retardation
assays with nuclear extracts preincubated with polyclonal an-
tiserum directed against GABPa or GABPb. These antisera
had been shown to inhibit GABP binding to its site in the distal
interleukin-2 (IL-2) enhancer (3). Whereas an unrelated anti-
FIG. 3. Factors binding in fp1 and fp2 cooperate in the transcriptional response to glucocorticoids in B cells. pGL-3 luciferase reporter plasmids were transiently
transfected into A20 cells (A, C, and D) or M12 cells (B) and stimulated (1 dex) or not (2 dex) with the glucocorticoid hormone dexamethasone (50 nM) for 5 h.
The relative luciferase (Luc.) activity was calculated as the ratio to the activity of the cotransfected SV40-Renilla luciferase internal standard. Individual experiments
are shown, which have been repeated with the same results at least twice. The error bars show the standard deviations between duplicate samples. (A and B) Luciferase
activities of plasmids containing a wild-type LTR (Lwt) or LTRs with mutations in fp1 and fp2 (Lm1,2), in fp1 (Lm1), or in fp2 (Lm2). Plasmid DP contained an LTR
lacking the sequences downstream of position 2105, including the promoter, and serves as a negative control. (C) Luciferase activity (1 dex) of plasmids containing
LTRs truncated at position 2303 (Twt and Tm1,2). (D) LTRs with mutations in the GRE are unresponsive to dexamethasone in A20 B cells. In the mutated LTRs
an octameric HindIII linker replaces the sequences between 2193 and 2162 (in L193m) or between 2175 and 2166 (in L175m).
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serum allowed the formation of specific complexes (Fig. 4A,
lanes 4 and 8), these were completely inhibited by anti-GABPa
(lanes 1 and 5) and partially inhibited by anti-GABPb (lanes 2
and 6) for both probes, fp1 as well as fp2 (Fig. 4A). Conversely,
to show that the fp1 and fp2 sequences can be bound by
GABP, the corresponding oligonucleotides were incubated
with recombinant GABPa or -b, or with both together, and
displayed in a gel retardation assay in parallel with the product
of incubation with a nuclear extract of A20 cells (Fig. 4B and
C). The addition of both a and b subunits of GABP resulted in
the formation of a complex with each of the probes (fp1 [Fig.
4B, lane 2] and fp2 [Fig. 4C, lane 3]) that comigrated with
those formed upon addition of nuclear extracts (Fig. 4B, lane
4, and C, lane 1). As GABPb is not a DNA-binding protein,
the faster-migrating complex is considered nonspecific.
GABPa bound less well than a and b together, in agreement
with the observation of a strong stabilizing effect of GABPb on
the DNA-binding activity of a (19, 23). The major complex (I)
formed by the nuclear extract comigrated with the ab complex
of recombinant proteins, confirming the identification of fp1
and fp2 as GABP binding sites. We could not convincingly
demonstrate an effect of a PEA3-specific antiserum on any
retarded complex of nuclear extracts with either probe, con-
sistent with the reports that PEA3 is normally expressed in
epithelial cells (61) and myoblasts (57) but not in B lympho-
cytes (J. A. Hassell, personal communication).
Redox sensitivity of the complexes. DNA binding and het-
erodimer formation of GABP are sensitive to redox. Both
functions require reducing conditions, and they are inhibited
by pro-oxidant agents both intracellularly and in nuclear ex-
FIG. 4. GABP binds to fp1 and fp2 and is present in complex I of B-cell extracts in a redox-sensitive form. (A to E) Gel retardation assays with end-labeled
oligonucleotide probes. (A) Specific antibodies against GABPa and/or GABPb (lanes 1 to 3 and 5 to 7) abolished the formation of complex I-GABPab (lanes 4 and
8) on 32P-labeled oligonucleotides containing either fp1 (1) or fp2 (2). A20 nuclear extracts were preincubated with the polyclonal antibodies (purified IgGs) prior to
addition of the probes. A similarly purified unrelated (Unrel) antibody was used as a negative control (lanes 4 and 8). (B and C) Recombinant GABPa (rGABPa)
and/or GABPb was incubated with the fp1 probe (B, lanes 1 to 3) or the fp2 probe (C, lanes 2 to 4) in parallel with A20 nuclear extracts (NE) (B, lane 4, and C, lane
1). ns, nonspecific complex (also present in the non-DNA-binding GABPb sample). (D and E) Redox sensitivity of complex formation in vitro. Treatment with NEM
(0.25, 0.5, or 5 mM) or DTT (2, 3, or 4 mM) for 20 min at 20°C was carried out in the binding reaction with A20 nuclear extracts and the fp1 (D) or the fp2 (E) probe.
(F) Redox sensitivity of reporter activity in vivo. M12 cells were cotransfected with a plasmid expressing thioredoxin (Trx; 0, 1, 3, or 6 mg) and a vector plasmid (to
a total of 6 mg) plus 0.75 pmol of a luciferase reporter under the control of either the wild-type LTR (Lwt) or an LTR with mutations in fp1 and fp2 (Lm1,2). The
cells were cultured in the presence of 1 mM H2O2 for 24 h, and dexamethasone (50 nM) was added to the 1dex samples during the last 4 h before harvesting. The
firefly luciferase activity of the extracts was measured and normalized to the SV40-Renilla luciferase activity of a cotransfected internal standard. The ratio of the activity
of Lwt to that of Lm1,2 was plotted as a function of the amount of cotransfected thioredoxin plasmid. The error bars indicate standard deviations. 1, present; 2, absent.
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tracts (15, 45). We tested whether this applied to the com-
plexes of B-cell extracts with fp1 and fp2. Nuclear extracts of
A20 cells were treated in vitro with increasing amounts of the
alkylating agent N-ethylmaleimide (NEM) or of DTT as a
control and then used in mobility shift assays with the fp1 or
fp2 probes. The results are shown in Fig. 4D and E. The lowest
concentration (0.25 mM) of NEM caused a reduction in the
intensity of the ab dimer band compared to that under reduc-
ing conditions (Fig. 4D and E, lanes 3 versus 6). Moreover, it
induced the appearance of a complex with higher mobility. We
think it may contain the a subunit alone, consistent with the
observation that the protein-protein interactions between the
a and b subunits are more sensitive to oxidative conditions
than the binding of GABPa to DNA (15). Increasing NEM
concentrations resulted in the disappearance of both DNA-ab
and DNA-a complexes (Fig. 4D and E, lane 1). We also tested
the sensitivity of the fp1-fp2 binding activity to intracellular
redox changes. A20 cells were treated for 2 h with the gluta-
thione-depleting agent DEM before nuclear extracts were pre-
pared (45). These in vivo-treated extracts, similarly to the in
vitro NEM-treated samples, were unable to form a complex
with either fp1 or fp2 (Fig. 5A, lane 2 versus lane 1 and 7 versus
6). Finally, it has been shown that the reducing protein thiore-
doxin regulates the DNA-binding activity of GABP (45) and
the transcriptional activity of the glucocorticoid receptor (44).
We therefore measured the activity of the luciferase reporter
with either the wild-type or the fp1-fp2-mutated LTR in M12
cells cotransfected with a plasmid expressing thioredoxin and
pretreated with H2O2 (Fig. 4F). To assess the contribution of
the fp1-fp2 mutation, the ratio of the activities (wild-type LTR
over mutated LTR) was plotted in Fig. 4F as a function of the
amount of cotransfected thioredoxin plasmid. In its absence,
no response to dexamethasone was observed (ratio, 1). The
intracellular expression of thioredoxin reestablished the hor-
monal response of the wild-type LTR but not that of the
mutated LTR (ratio, .1). These data show that the fp1-fp2
binding activity is regulated by redox conditions in vitro and in
vivo, in agreement with its identification as GABP.
Formation of heterotetrameric complexes. GABP forms an
a2b2 tetramer on tandemly arranged sites (like those in the
immediate-early promoter of herpes simplex virus) through a
leucine zipper domain at the carboxyl terminus of GABPb
(19). As fp1 and fp2 form an analogous arrangement in the
MMTV LTR, separated by 8 bp, we investigated the binding
properties of a double-stranded oligonucleotide comprising
both fp1 and fp2. In a gel retardation assay, a complex with
very low mobility is clearly visible (Fig. 5A, lane 4) above the
ab band. It is tentatively identified as a2b2, although its stoi-
chiometry is not known. A complex with the same mobility was
detected with recombinant GABPa plus -b (Fig. 5B, lane 2),
whereas the addition of GABPa alone produced a faint lower
band (possibly an a2 complex [Fig. 5B, lane 1]). In agreement
with their putative identifications, both cellular a2b2 and ab
complexes disappeared upon in vitro treatment of the nuclear
extract with the alkylating agent NEM (Fig. 5A, lane 3). An
extract from cells treated in vivo with DEM did not form any
heterotetramers on the fp1-fp2 probe (Fig. 5A, lane 5),
whereas some ab dimers, and predominantly a monomers,
were detectable, suggesting that the in vivo oxidation of the
relevant cysteines of GABPa had been incomplete. Compared
to the total suppression of complex formation on single-site
probes (Fig. 5A, lanes 2 and 7), the partial effect on the double-
site probe (Fig. 5A, lane 5) may be due to cooperativity of
GABP binding. In conclusion, the DNA-binding activity to the
fp1 and fp2 sites present in nuclear extracts of B-cell lines was
identified as the heterodimeric Ets family member GABP,
based on its electrophoretic mobility, reactivity with specific
antisera, comigration with recombinant proteins, and sensitiv-
ity to redox conditions.
FIG. 5. Redox-sensitive GABP tetramers are formed by B-cell nuclear extracts on a probe containing both fp1 and fp2. (A) Gel retardation assay with A20 nuclear
extracts and oligonucleotide probe fp1 (1), fp2 (2), or fp1-fp2 (D; see Fig. 2B). With probe D, a slower-migrating band is detected (lane 4). By analogy to the complex
formed by recombinant GABP, and to those observed with similarly arranged Ets sites of known genes, it is tentatively identified as the tetrameric from of GABP and
is labeled a2b2. Treatment with alkylating agents eliminated the tetrameric complex, in vitro by adding NEM (20 min; 20°C) to the binding reaction (lane 3) or in vivo
by using a nuclear extract of DEM-treated cells (lane 5). On the single-site probes as well, DEM treatment of the cells used for the nuclear extract eliminated the ab
complex (lanes 2 versus 1 and 7 versus 6). (B) For comparison, tetramer formation on probe D by a mixture of recombinant GABPa (rGABPa) and GABPb (lane
2). 1, present; 2, absent. ns, nonspecific complex.
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Functional cooperation of GABP with the glucocorticoid
response. We have shown (Fig. 3) that mutations which pre-
vent GABP binding to the fp1 and fp2 sites abolished the
transcriptional stimulation elicited by dexamethasone in B-cell
lines. As the fp1 and fp2 sites are contiguous to the distal GRE,
which mediates the glucocorticoid response (Fig. 3D), the en-
dogenous GABP of B cells may improve the binding or the
activation properties of the glucocorticoid receptor. To test if
added exogenous GABP is able to further increase the stimu-
lated expression from the MMTV-LTR–luciferase reporter
plasmid, we cotransfected M12 cells with expression vectors for
the cDNAs of the GABP subunits, singly or together. As shown
in Fig. 6A, a twofold increase in luciferase activity was ob-
served even with the lowest dose (1 mg) of GABP plasmids,
especially with both subunits. Single subunits were also effec-
tive, probably in cooperation with endogenous GABP. With
increasing amounts of GABP (3 or 6 mg), a maximum increase
of approximately threefold was obtained, approaching a pla-
FIG. 6. Exogenous GABP increases glucocorticoid-stimulated reporter activity in M12 cells (A and C) and L cells (B) in an fp1-fp2-dependent manner (B and C);
exogenous glucocorticoid receptor synergizes with GABP (D) and requires fp1 and fp2 (E) in M12 cells. (A) The expression plasmids sRSV-GABPa and/or
sRSV-GABPb1 (0, 1, 3, or 6 mg) plus the control plasmid pRSV-TK (Co) to a total amount of 12 mg were transiently cotransfected with 0.75 pmol of wild-type
LTR-(firefly) luciferase plasmid into M12 cells, which were treated with dexamethasone (50 nM). (B) 6 mg of pRSV-TK (Co) or 3 mg of sRSV-GABPa and/or sGABPb1
plus pRSV-TK to a total of 6 mg were cotransfected with 0.75 pmol of wild-type (Lwt) or fp1-fp2-mutated (Lm1,2) LTR-luciferase reporter constructs into Ltk2 cells,
which were treated with 100 nM dexamethasone (1 dex). (C) Three micrograms each of sRSV-GABPa and sRSV-GABPb1 expression plasmids (ab) or 6 mg of
pRSV-TK (Co) was cotransfected with 0.75 pmol of wild-type (Lwt) or fp1-fp2-mutated (Lm1,2) LTR-luciferase constructs into M12 cells, which were treated (1 dex)
or not (2 dex) with dexamethasone (50 nM). (D) Synergistic effect of GABP and the glucocorticoid receptor (GR). M12 cells were transfected with 0.75 pmol of Lwt
plus 9 mg of pRSV-TK (Co) or 3 mg each of sRSV-GABPa and sRSV-GABPb1 (ab) and/or 3 mg of pRSVhGRa (GR). pRSV-TK was added to a total amount of
9 mg per transfection. The cells were treated (1 dex) or not (2 dex) with 50 nM dexamethasone. (E) Overexpressed glucocorticoid receptor required fp1 and fp2 as
well as the GRE for glucocorticoid stimulation in M12 cells. Three micrograms of pSG5mGR (GR) or of pSV2-neo control plasmid (Co) was cotransfected with 0.75
pmol of LTR-luciferase constructs containing either the wild-type LTR (Lwt), an LTR with the mutation LS 175/2166 in the GRE (L175m), the fp1-fp2-mutated LTR
(Lm1,2), or the promoterless DP plasmid as a negative control. The cells were treated with 50 nM dexamethasone. In panel E, the firefly luciferase (Luc.) activities
of the extracts were measured and normalized to the SV40-Renilla luciferase activity of a cotransfected internal standard. In panels A to D, the luciferase activity is
expressed in arbitrary units with respect to the protein content. Individual experiments are shown, which have been repeated with the same results at least twice. The
error bars show the standard deviations between duplicate samples.
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teau. For comparison, we cotransfected the same plasmids into
Ltk2 cells, which contain a relatively large amount of glucocor-
ticoid receptor (Fig. 1) (47) but do not show any presence of
GABP in mobility shift assays with the fp1 or fp2 probe or with
a consensus GABP binding probe (not shown). The results
(Fig. 6B) show an fp1- and fp2-dependent increase of dexa-
methasone-induced reporter activity of approximately twofold
with either GABPa alone or a plus b; GABPb alone had no
effect, consistent with its inability to bind DNA and with the
absence of endogenous GABPa in L cells. In M12 cells as well,
the increase of dexamethasone-stimulated activity by GABPab
was dependent on the fp1 and fp2 sequences, whereas no effect
was observed on the uninduced basal level (Fig. 6C). We con-
clude that GABP is able to cooperate functionally with the
endogenous glucocorticoid receptor. Since the expression of
exogenous GABP in M12 B cells showed a saturation of re-
porter activity (Fig. 6A), the level of endogenous receptor may
be limiting. We therefore asked if the dexamethasone response
could be improved by expressing exogenous receptor and if its
action remained dependent on GABP. The results shown in
Fig. 6D indicate that cotransfection of an expression vector for
the glucocorticoid receptor increased the dexamethasone re-
sponse of M12 cells approximately 15-fold and moreover co-
operated synergistically with coexpressed GABP. This remark-
able increment was dependent on the GRE (as expected) but
also, to a similar extent, on the fp1 and fp2 motifs (Fig. 6E).
DISCUSSION
In this study, we have identified a novel regulatory region in
the MMTV promoter that contains tandem Ets-like binding
motifs and interacts with the heterodimeric Ets factor GABP
present in mature B-cell lines. In these cells, mutation of both
GABP binding sites abolished the transcriptional stimulation
elicited by glucocorticoid hormones, and expression of exoge-
nous GABP increased it, indicating a functional cooperation
with the glucocorticoid receptor bound to the adjacent GRE.
The GABP binding site in MMTV DNA between positions
2140 and 2165 is composed of a dyad symmetry element with
the GGA(A/T) core sequences directed to the center of the
dyad. Of the two components of the dyad, fp1 shows a better
homology (8 out of 10 bp) to the optimal GABP binding site
(10), whereas fp2 is less related (5 out of 10 bp). This may
explain their different efficiencies at binding recombinant
GABP (Fig. 4B and C). A similar internal arrangement of the
dyad is found in the GABP site of the distal IL-2 enhancer, and
it was described as rather unfavorable for the formation of
a2b2 heterotetramers (3). Indeed, recombinant a2b2 com-
plexes were only a minor fraction of those formed on the
fp1-fp2 oligonucleotide (Fig. 5). Structural features of the
DNA-protein contacts have been described for a direct repeat
of core elements (6, 28). On the other hand, a palindrome with
the core elements directed in opposite directions, as in the
IL-16 promoter, was shown to favor heterotetramer formation
(4). A relative autonomy of the individual ab dimers on each
site is suggested by the functional analysis of reporters carrying
mutations in either fp1 or fp2 that showed additivity and not
synergism of their activities (Fig. 3A and B). At first sight, the
function of the GABP binding sequences might seem to be to
stabilize the binding of glucocorticoid receptor molecules on
the GRE, especially if they are present in low abundance, as
suggested by the absence of a footprint over the GRE with
M12 nuclear extracts (Fig. 1). However, overexpression of the
receptor was unable to overcome the need for GABP binding,
and the integrity of the GABP sites was still required as much
as the integrity of the GRE (Fig. 6E). With mutants either in
the GRE or in the fp1-fp2 sequence, the residual activity ob-
served with overexpressed receptor might be due to protein-
protein interactions between the receptor and GABP. These
data suggest that the role of GABP in B cells goes beyond a
mere stabilization of receptor binding to DNA and may involve
a transactivation function. Moreover, coexpression of GABP
and receptor resulted in a synergistic enhancement of the hor-
mone response (Fig. 6D). An autonomous transactivating do-
main is present in the b subunit of GABP, but none has been
described so far in the a subunit (30, 53). On the other hand,
it was the a subunit which showed cooperativity with endoge-
nous glucocorticoid receptor in the transfection experiment
with L cells (Fig. 6B). It is likely that the fp1 and fp2 sites are
also occupied by Ets factors in Ltk2 cells, because their mu-
tation decreased the dexamethasone-induced luciferase level
by two- to threefold. These putative Ets factors should be
different from GABPa, as they cannot cooperate with trans-
fected GABPb (Fig. 6B) and can be replaced by GABPa more
efficiently, probably because of its overexpression. Identifying
the domains in GABP that are responsible for cooperation
with the glucocorticoid response will give new insights into the
complexity of the mechanisms of MMTV gene regulation by
protein-protein interactions. Candidate proteins for conferring
transactivation functions on GABP in the context of the
MMTV promoter are the nuclear coactivators CBP and p300
(reviewed in reference 35), which were recently shown to bind
to GABPa and enhance the induction of the IL-16 promoter
(4). The prototype Ets factor, Ets-1, was also shown to coop-
erate with CBP and p300, though the synergism was modest,
suggesting that further cell or promoter requirements and/or
factors are needed (63). It must be noted that the IL-16 pro-
moter, like most promoters activated by GABP, lacks a TATA
box, unlike to the MMTV promoter. Whether the mechanisms
of transactivation would be the same when a steroid receptor
plus GABP interacts with a TATA-box-containing promoter
will have to be determined. GABP was found to be widely
expressed in tissues (19, 37), yet it has been shown to command
the regulation of several genes which are expressed in cell-
type-specific patterns. Such selectivity depends in part on the
nature of the DNA-GABPa interactions and on regulation
imparted by its association with GABPb (28). Several of these
genes contain neither a TATA box nor a classical initiator
element, and GABP functions in them as a promoter element.
In our study, no effect of mutations in fp1 and fp2 on the basal,
uninduced transcriptional activity of the MMTV promoter was
detected. In gel retardation assays with the fp1 or fp2 probe
and nuclear extracts of mouse Ltk2 cells, GR mammary tumor
cells, or rat FTO-2B hepatoma cells, we did not detect any
complex with the migration property of a GABP heterodimer
(data not shown). It is a general characteristic of Ets factors to
function in cooperation with other transcription factors (re-
viewed in reference 60). Among the partners described for
GABP, one finds Jun-Fos (AP-1) (5), Sp-1 (64), c-Myb, and
C/EBP (48). Few reports are concerned with possible interac-
tions of Ets factors with nuclear receptors. In the rat tyrosine
aminotransferase gene, an Ets binding site of the 22.5-kb
enhancer showed a weak cooperation with a neighboring GRE
(22). A cross inhibition between exogenously expressed PU.1
(an Ets factor) and glucocorticoid receptor was observed with
promoter constructs carrying the respective DNA regulatory
elements (25). In the promoter of matrix metalloproteinases,
an Ets binding site which is required for positive regulation in
cooperation with an AP-1 site was shown to be the target of
repression by the androgen receptor but not by other steroid
(e.g., glucocorticoid) receptors (55).
Previous studies of regulatory functions of the MMTV LTR
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pointed to sequences in the 2140-to-2160 area as having neg-
ative effects, mainly on the basal level of transcription (32, 39,
40). A report on an activity affecting the glucocorticoid stim-
ulation in a particular rat hepatoma cell line showed a negative
effect as well (56). These observations are in contrast to the
role of fp1-fp2 in B cells described here, which is a positive one
that affects the glucocorticoid-stimulated expression, not the
basal level. In the course of its life cycle, MMTV replicates in
lymphocytes, with B cells as the first targets of viral infection.
Apart from the expression of the superantigen RNA encoded
in the 39 LTR, for which separate promoters located in the env
gene have been identified (2, 49, 50, 65), all other viral genes
are transcribed from the major proviral promoter in the LTR.
In a search for B-cell-specific transcriptional elements, it was
not expected to find one that also relied on the glucocorticoid
receptor. Our results suggest a necessary cooperation of
GABP with the glucocorticoid receptor that may have biolog-
ical relevance for cells containing low levels of receptor, like
the mature B-cell lines used in this study. The basal activity of
the MMTV promoter is higher in B-cell lines and in primary B
cells than in mammary cells (16). Thus, two scenarios for
MMTV expression seem to occur in vivo, one in mammary
cells, consisting of a very low basal level with a very high
hormonal stimulation of promoter activity, and one in B lym-
phocytes, characterized by a moderate basal level and a mod-
erate glucocorticoid induction with the help of GABP, a non-
receptor factor. The data reported here concern a striking
functional cooperation of GABP with the glucocorticoid re-
ceptor at a natural viral promoter. They provide the possibility
to investigate the requirements for binding site arrangement
and for specific protein domains. Moreover, as Ets factors in
general (60), and GABP in particular (23), have been shown to
be targets of the Ras-MAP kinase signal transduction cascade,
they offer a novel example of regulatory possibilities at the
intersection of two signaling pathways with a wide range of
biological effects.
ACKNOWLEDGMENTS
We thank Egbert Flory for his generous gift of GABP reagents
(expression vectors, recombinant proteins, and antisera), Isabelle Ker-
blat for the thioredoxin plasmid, and, for the glucocorticoid receptor
plasmids, Ron Evans (human glucocorticoid receptor) and Malcolm
Parker (mouse glucocorticoid receptor). We also thank our colleagues
Eithne Costello and Roland Sahli for technical advice and Markus
Nabholz and Roland Sahli for critical reading of the manuscript.
This work was supported by the Swiss National Science Fund.
REFERENCES
1. Acha-Orbea, H., and H. R. MacDonald. 1995. Superantigens of mouse mam-
mary tumor virus. Annu. Rev. Immunol. 13:459–486.
2. Arroyo, J., E. Winchester, B. S. McLellan, and B. T. Huber. 1997. Shared
promoter elements between a viral superantigen and the major histocom-
patibility complex class II-associated invariant chain. J. Virol. 71:1237–1245.
3. Avots, A., A. Hoffmeyer, E. Flory, A. Cimanis, U. R. Rapp, and E. Serfling.
1997. GABP factors bind to a distal interleukin 2 (IL-2) enhancer and
contribute to c-Raf-mediated increase in IL-2 induction. Mol. Cell. Biol.
17:4381–4389.
4. Bannert, N., A. Avots, M. Baier, E. Serfling, and R. Kurth. 1999. GA-binding
protein factors, in concert with the coactivator CREB binding protein/p300,
control the induction of the interleukin 16 promoter in T lymphocytes. Proc.
Natl. Acad. Sci. USA 96:1541–1546.
5. Basuyaux, J. P., E. Ferreira, D. Stehelin, and G. Buttice`. 1997. The Ets
transcription factors interact with each other and with the c-Fos/c-Jun com-
plex via distinct protein domains in a DNA-dependent and -independent
manner. J. Biol. Chem. 272:26188–26195.
6. Batchelor, A. H., D. E. Piper, F. C. de la Brousse, S. L. McKnight, and C.
Wolberger. 1998. The structure of GABPa/b: an ETS domain-ankyrin repeat
heterodimer bound to DNA. Science 279:1037–1041.
7. Beato, M. 1989. Gene regulation by steroid hormones. Cell 56:335–344.
8. Bittner, J. J. 1936. Some possible effects of nursing on the mammary gland
tumor incidence in mice. Science 84:162–169.
9. Blake, M. C., R. C. Jambou, A. G. Swick, J. W. Kahn, and J. C. Azizkhan.
1990. Transcriptional initiation is controlled by upstream GC-box interac-
tions in a TATAA-less promoter. Mol. Cell. Biol. 10:6632–6641.
10. Brown, T. A., and S. L. McKnight. 1992. Specificities of protein-protein and
protein-DNA interaction of GABP a and two newly defined ets-related
proteins. Genes Dev. 6:2502–2512.
11. Buetti, E. 1994. Stably integrated mouse mammary tumor virus long terminal
repeat DNA requires the octamer motifs for basal promoter activity. Mol.
Cell. Biol. 14:1191–1203.
12. Buetti, E., and B. Ku¨hnel. 1986. Distinct sequence elements involved in the
glucocorticoid regulation of the mouse mammary tumor virus promoter
identified by linker scanning mutagenesis. J. Mol. Biol. 190:379–389.
13. Cardiff, R. D., and L. J. T. Young. 1980. Mouse mammary tumor biology: a
new synthesis, p. 1105–1114. In M. Essex, G. Todaro, and H. Zur Hausen
(ed.), Viruses in naturally occurring cancers. Cold Spring Harbor Labora-
tory, Cold Spring Harbor, N.Y.
14. Cavin, C., and E. Buetti. 1995. Tissue-specific and ubiquitous factors binding
next to the glucocorticoid receptor modulate transcription from the mouse
mammary tumor virus promoter. J. Virol. 69:3759–3770.
15. Chinenov, Y., T. Schmidt, X. Y. Yang, and M. E. Martin. 1998. Identification
of redox-sensitive cysteines in GA-binding protein-a that regulate DNA
binding and heterodimerization. J. Biol. Chem. 273:6203–6209.
16. Corley, R. B., F. E. Lund, T. D. Randall, L. B. King, S. Doerre, and D. L.
Woodland. 1992. Mouse mammary tumor proviral gene expression in cells of
the B lineage. Semin. Immunol. 4:287–296.
17. Costello, E., P. Saudan, E. Winocour, L. Pizer, and P. Beard. 1997. High
mobility group chromosomal protein 1 binds to the adeno-associated virus
replication protein (Rep) and promotes Rep-mediated site-specific cleavage
of DNA, ATPase activity and transcriptional repression. EMBO J. 16:5943–
5954.
18. Danielsen, M., J. P. Northrop, and G. M. Ringold. 1986. The mouse glu-
cocorticoid receptor: mapping of functional domains by cloning, sequencing
and expression of wild-type and mutant receptor proteins. EMBO J. 5:2513–
2522.
19. de la Brousse, F. C., E. H. Birkenmeier, D. S. King, L. B. Rowe, and S. L.
McKnight. 1994. Molecular and genetic characterization of GABP b. Genes
Dev. 8:1853–1865.
20. Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcrip-
tion initiation by RNA polymerase II in a soluble extract from isolated
mammalian nuclei. Nucleic Acids Res. 11:1475–1489.
21. Dzuris, J. L., T. V. Golovkina, and S. R. Ross. 1997. Both T and B cells shed
infectious mouse mammary tumor virus. J. Virol. 71:6044–6048.
22. Espina´s, M. L., J. Roux, J. Ghysdael, R. Pictet, and T. Grange. 1994. Par-
ticipation of Ets transcription factors in the glucocorticoid response of the
rat tyrosine aminotransferase gene. Mol. Cell. Biol. 14:4116–4125.
23. Flory, E., A. Hoffmeyer, U. Smola, U. R. Rapp, and J. T. Bruder. 1996. Raf-1
kinase targets GA-binding protein in transcriptional regulation of the human
immunodeficiency virus type 1 promoter. J. Virol. 70:2260–2268.
24. Galas, D. J., and A. Schmitz. 1978. DNAse footprinting: a simple method for
the detection of protein-DNA binding specificity. Nucleic Acids Res. 5:3157–
3170.
25. Gauthier, J. M., B. Bourachot, V. Doucas, M. Yaniv, and F. Moreau-Gach-
elin. 1993. Functional interference between the Spi-1/PU.1 oncoprotein and
steroid hormone or vitamin receptors. EMBO J. 12:5089–5096.
26. Gigue`re, V., S. M. Hollenberg, M. G. Rosenfeld, and R. M. Evans. 1986.
Functional domains of the human glucocorticoid receptor. Cell 46:645–652.
27. Gorski, K., M. Carneiro, and U. Schibler. 1986. Tissue-specific in vitro
transcription from the mouse albumin promoter. Cell 47:767–776.
28. Graves, B. J. 1998. Inner workings of a transcription factor partnership.
Science 279:1000–1002.
29. Grosschedl, R., and D. Baltimore. 1985. Cell-type specificity of immunoglob-
ulin gene expression is regulated by at least three DNA sequence elements.
Cell 41:885–897.
30. Gugneja, S., J. V. Virbasius, and R. C. Scarpulla. 1995. Four structurally
distinct, non-DNA-binding subunits of human nuclear respiratory factor 2
share a conserved transcriptional activation domain. Mol. Cell. Biol. 15:102–
111.
31. Gu¨nzburg, W. H., and B. Salmons. 1992. Factors controlling the expression
of mouse mammary tumour virus. Biochem. J. 283:625–632.
32. Ha¨rtig, E., B. Nierlich, S. Mink, G. Nebl, and A. C. Cato. 1993. Regulation
of expression of mouse mammary tumor virus through sequences located in
the hormone response element: involvement of cell-cell contact and a neg-
ative regulatory factor. J. Virol. 67:813–821.
33. Held, W., G. A. Waanders, A. N. Shakhov, L. Scarpellino, H. Acha-Orbea,
and H. R. MacDonald. 1993. Superantigen-induced immune stimulation
amplifies mouse mammary tumor virus infection and allows virus transmis-
sion. Cell 74:529–540.
34. Higuchi, T. 1991. Recombinant PCR, p. 177–183. In M. A. Innis, D. H.
Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols. Academic Press,
San Diego, Calif.
35. Janknecht, R., and T. Hunter. 1996. Versatile molecular glue. Transcrip-
tional control. Curr. Biol. 6:951–954.
VOL. 74, 2000 GABP COOPERATION IN THE GLUCOCORTICOID RESPONSE 4997
36. Ku¨hnel, B., E. Buetti, and H. Diggelmann. 1986. Functional analysis of the
glucocorticoid regulatory elements present in the mouse mammary tumor
virus long terminal repeat. A synthetic distal binding site can replace the
proximal binding domain. J. Mol. Biol. 190:367–378.
37. LaMarco, K., C. C. Thompson, B. P. Byers, E. M. Walton, and S. L. McK-
night. 1991. Identification of Ets- and notch-related subunits in GA binding
protein. Science 253:789–792.
38. LaMarco, K. L., and S. L. McKnight. 1989. Purification of a set of cellular
polypeptides that bind to the purine-rich cis-regulatory element of herpes
simplex virus immediate early genes. Genes Dev. 3:1372–1383.
39. Langer, S. J., and M. C. Ostrowski. 1988. Negative regulation of transcrip-
tion in vitro by a glucocorticoid response element is mediated by a trans-
acting factor. Mol. Cell. Biol. 8:3872–3881.
40. Lee, J. W., P. G. Moffitt, K. L. Morley, and D. O. Peterson. 1991. Multipartite
structure of a negative regulatory element associated with a steroid hor-
mone-inducible promoter. J. Biol. Chem. 266:24101–24108.
41. Lichtsteiner, S., J. Wuarin, and U. Schibler. 1987. The interplay of DNA-
binding proteins on the promoter of the mouse albumin gene. Cell 51:963–
973.
42. Liu, J., D. Bramblett, Q. Zhu, M. Lozano, R. Kobayashi, S. R. Ross, and J. P.
Dudley. 1997. The matrix attachment region-binding protein SATB1 partic-
ipates in negative regulation of tissue-specific gene expression. Mol. Cell.
Biol. 17:5275–5287.
43. Luther, S. A., and H. Acha-Orbea. 1997. Mouse mammary tumor virus:
immunological interplays between virus and host. Adv. Immunol. 65:139–
243.
44. Makino, Y., N. Yoshikawa, K. Okamoto, K. Hirota, J. Yodoi, I. Makino, and
H. Tanaka. 1999. Direct association with thioredoxin allows redox regulation
of glucocorticoid receptor function. J. Biol. Chem. 274:3182–3188.
45. Martin, M. E., Y. Chinenov, M. Yu, T. K. Schmidt, and X. Y. Yang. 1996.
Redox regulation of GA-binding protein-a DNA binding activity. J. Biol.
Chem. 271:25617–25623.
46. Maxam, A. M., and W. Gilbert. 1980. Sequencing end-labeled DNA with
base-specific chemical cleavages. Methods Enzymol. 65:499–560.
47. Meulia, T., and H. Diggelmann. 1990. Tissue-specific factors and glucocor-
ticoid receptors present in nuclear extracts bind next to each other in the
promoter region of mouse mammary tumor virus. J. Mol. Biol. 216:859–872.
48. Nuchprayoon, I., C. P. Simkevich, M. Luo, A. D. Friedman, and A. G.
Rosmarin. 1997. GABP cooperates with c-Myb and C/EBP to activate the
neutrophil elastase promoter. Blood 89:4546–4554.
49. Reuss, F. U., and J. M. Coffin. 1995. Stimulation of mouse mammary tumor
virus superantigen expression by an intragenic enhancer. Proc. Natl. Acad.
Sci. USA 92:9293–9297.
50. Reuss, F. U., and J. M. Coffin. 1998. Mouse mammary tumor virus superan-
tigen expression in B cells is regulated by a central enhancer within the pol
gene. J. Virol. 72:6073–6082.
51. Ringold, G. M. 1985. Steroid hormone regulation of gene expression. Annu.
Rev. Pharmacol. Toxicol. 25:529–566.
52. Rollini, P., J. Billotte, E. Kolb, and H. Diggelmann. 1992. Expression pattern
of mouse mammary tumor virus in transgenic mice carrying exogenous
proviruses of different origins. J. Virol. 66:4580–4586.
53. Sawada, J., M. Goto, C. Sawa, H. Watanabe, and H. Handa. 1994. Tran-
scriptional activation through the tetrameric complex formation of E4TF1
subunits. EMBO J. 13:1396–1402.
54. Sawadogo, M., and R. G. Roeder. 1985. Interaction of a gene-specific tran-
scription factor with the adenovirus major late promoter upstream of the
TATA box region. Cell 43:165–175.
55. Schneikert, J., H. Peterziel, P. A. Defossez, H. Klocker, Y. Launoit, and A. C.
Cato. 1996. Androgen receptor-Ets protein interaction is a novel mechanism
for steroid hormone-mediated down-modulation of matrix metalloprotein-
ase expression. J. Biol. Chem. 271:23907–23913.
56. Tanaka, H., Y. Dong, Q. Li, S. Okret, and J. A. Gustafsson. 1991. Identifi-
cation and characterization of a cis-acting element that interferes with glu-
cocorticoid-inducible activation of the mouse mammary tumor virus pro-
moter. Proc. Natl. Acad. Sci. USA 88:5393–5397.
57. Taylor, J. M., E. E. Dupont-Versteegden, J. D. Davies, J. A. Hassell, J. D.
Houle, C. M. Gurley, and C. A. Peterson. 1997. A role for the ETS domain
transcription factor PEA3 in myogenic differentiation. Mol. Cell. Biol. 17:
5550–5558.
58. Toohey, M. G., J. W. Lee, M. Huang, and D. O. Peterson. 1990. Functional
elements of the steroid hormone-responsive promoter of mouse mammary
tumor virus. J. Virol. 64:4477–4488.
59. van Leeuwen, F., and R. Nusse. 1995. Oncogene activation and oncogene
cooperation in MMTV-induced mouse mammary cancer. Semin. Cancer
Biol. 6:127–133.
60. Wasylyk, B., J. Hagman, and A. Gutierrez-Hartmann. 1998. Ets transcription
factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends
Biochem. Sci. 23:213–216.
61. Xin, J. H., A. Cowie, P. Lachance, and J. A. Hassell. 1992. Molecular cloning
and characterization of PEA3, a new member of the Ets oncogene family
that is differentially expressed in mouse embryonic cells. Genes Dev. 6:481–
496.
62. Yanagawa, S., A. Murakami, and H. Tanaka. 1990. Extra mouse mammary
tumor proviruses in DBA/2 mouse lymphomas acquire a selective advantage
in lymphocytes by alteration in the U3 region of the long terminal repeat.
J. Virol. 64:2474–2483.
63. Yang, C., L. H. Shapiro, M. Rivera, A. Kumar, and P. K. Brindle. 1998. A
role for CREB binding protein and p300 transcriptional coactivators in Ets-1
transactivation functions. Mol. Cell. Biol. 18:2218–2229.
64. Yu, M., X. Y. Yang, T. Schmidt, Y. Chinenov, R. Wang, and M. E. Martin.
1997. GA-binding protein-dependent transcription initiator elements. Effect
of helical spacing between polyomavirus enhancer a factor 3 (PEA3)/Ets-
binding sites on initiator activity. J. Biol. Chem. 272:29060–29067.
65. Zhang, D. J., V. K. Tsiagbe, C. Huang, and G. J. Thorbecke. 1996. Control
of endogenous mouse mammary tumor virus superantigen expression in SJL
lymphomas by a promoter within the env region. J. Immunol. 157:3510–3517.
4998 AURREKOETXEA-HERNA´NDEZ AND BUETTI J. VIROL.
